Repatha (evolocumab) / Dr. Reddy’s, Amgen, Astellas - LARVOL DELTA

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=250 | Recruiting | Sponsor: Hoffmann-La Roche | N=410 ➔ 250

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Active, not recruiting | Sponsor: Hoffmann-La Roche | N=675 ➔ 314

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=410 | Recruiting | Sponsor: Hoffmann-La Roche | N=292 ➔ 410

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=307 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2024 ➔ Nov 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=380 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Apr 2022 ➔ Nov 2023

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=675 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Jun 2026 ➔ Sep 2025 | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2027 ➔ Nov 2026

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=470 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Aug 2025 ➔ Nov 2026 | Trial primary completion date: Apr 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=675 | Recruiting | Sponsor: Hoffmann-La Roche | N=470 ➔ 675 | Trial completion date: Nov 2026 ➔ Sep 2027 | Trial primary completion date: Aug 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2026 ➔ Nov 2025

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Feb 2022 ➔ Jun 2022

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=435 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2023 ➔ Aug 2025 | Trial primary completion date: Feb 2022 ➔ Apr 2024

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=307 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1/2 trial • Non Small Cell Lung Cancer • PD-L1

CHORMONE: The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis (clinicaltrialsregister.eu) - P4 | N=250 | Recruiting | Sponsor: Medical University Of Vienna | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Dyslipidemia • Mood Disorders • Osteoporosis • Psychiatry • Rheumatology

Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial. (PubMed, Clin Res Cardiol) - P=N/A | "Compared with placebo, the addition of evolocumab did not yield incremental improvements in lesion-level atheroma burden in the first 12 weeks after ACS. However, in the pooled analysis, significant short-term reductions in atheroma volume and plaque lipid content were observed."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. (PubMed, Front Med (Lausanne)) - "According to the medical records, all patients were categorized into the Control group (n = 30, atorvastatin 20 mg QN) and the PCSK9i group (n = 30, evolocumab injection 140 mg Q2W in addition to atorvastatin). Multivariable regression analyses demonstrated the superior improvement in CAP and FLI observed with PCSK9-i is independent of concomitant sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy. PCSK9i effectively reduced hepatic steatosis surrogate scores (FLI, CAP) and lipid levels (TC, LDL-C) in patients with MAFLD combined with T2DM."

Journal • Diabetes • Dyslipidemia • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting. (PubMed, Front Cardiovasc Med) - "All received high-intensity statin therapy ± ezetimibe (STANDARD, n = 43), while 31 also received evolocumab 140 mg every two weeks (EVOLOCUMAB), initiated pre-angiography, preoperatively, or within 72 h post-CABG. Given the retrospective observational design, causal inference is limited and residual confounding cannot be excluded. These findings are hypothesis-generating and require confirmation in randomized trials."

Journal • Observational data • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Diabetes • Metabolic Disorders

RECURRENT PANCREATITIS: IDENTIFYING FAMILIAL CHYLOMICRONEMIA SYNDROME IN AN ADULT (ACC 2026) - "Her pancreatitis occurred despite maximal lifestyle (strict low-fat diet, alcohol abstinence, BMI of 24, apolipoprotein B 75mg/dL) and medical therapy (fenofibrate, gemfibrozil, icosapent ethyl, rosuvastatin, evolocumab, and levocarnitine)...She was subsequently started on olezarsen, which lowered TG to 100 mg/dL... FCS is a rare and underdiagnosed genetic form of HTG. This case highlights the importance of evaluating for FCS in adults with refractory HTG in the absence of secondary factors. Accurate classification enables the use of precision therapy, such as APOC3 inhibition, which may improve outcomes."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Familial Chylomicronemia Syndrome • Heart Failure • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia • APOB • LPL

Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • Atherosclerosis • Cardiovascular

PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY USING AI-BASED MURRAY LAW-DERIVED QUANTITATIVE FLOW RATIO (µFR): INSIGHTS FROM THE YELLOW III STUDY (ACC 2026) - "Evolocumab added to HIST is associated with modest but statistically significant improvements in coronary physiology, as measured by angiography-derived µFR. Aggressive lipid-lowering may improve not only plaque morphology but also functional coronary physiology , even in non-obstructive lesions"

BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma (YouTube) - "Tian Zhang, MD...describes the Phase II BOOST-RCC trial (NCT06284564) of evolocumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mRCC) refractory to prior immune checkpoint inhibitors. By inhibiting pcsk9 to potentially enhance tumor antigen presentation and overcome resistance, the study assesses objective response rates and safety. Utilizing a 2-stage design, this investigator-initiated trial aims to determine if adding evolocumab improves outcomes in this difficult-to-treat population. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA."

Video • Renal Cell Carcinoma

HOW LOW CAN WE GO: TRENDS IN CHOLESTEROL MANAGEMENT AFTER CORONARY REVASCULARIZATION ACROSS A MUTLI-CENTER HEALTH SYSTEM (ACC 2026) - "Groups with LDL≥ 100, ≥70, and ≥55 had a greater use of ezetimibe and evolocumab. Those with more cardiovascular risk factors identified were able to achieve lower LDL levels. Those with higher LDL levels had a greater prevalence of additional therapies beyond statins. This calls for further investigation into why physicians are more successful in achieving lower LDL in individuals with medical conditions that heighten cardiovascular risk."

Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Nephrology

IMPACT OF MAXIMAL LIPID LOWERING THERAPY ON THE PHYSIOLOGICAL DISEASE PATTERN USING AI BASED VIRTUAL µFR PULLBACK CURVE: INSIGHTS FROM THE YELLOW III STUDY (ACC 2026) - "Addition of evolocumab to high-intensity statin therapy (HIST) was associated with a significant improvement in PPG. LCBI4mm responders had more commonly diffuse disease."